Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of ARI-3037MO compared to
placebo in reducing low-density lipoprotein cholesterol (LDL-C) levels in subjects with
dyslipidemia.